DeepMed Research

Yuhan Corporation

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

PK and Food Effect of Pregabalin Study After Dosing in Healthy Male Volunteers

Phase 1

Completed

Conditions: Peripheral Neuropathy Pain

Interventions: Drug: Lyrica
Drug: YHD1119

First Posted Date: 2016-05-26

Last Posted Date: 2019-01-16

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 64

Registration Number: NCT02783638

Locations: 🇰🇷
Chonbuk National University Hospital, Jeonju, Korea, Republic of

A Clinical Trial of YH23537 in Patients With Knee Osteoarthritis

Phase 2

Completed

Conditions: Knee Osteoarthritis

Interventions: Drug: YH23537
Drug: YH23537 placebo
Drug: Celecoxib

First Posted Date: 2016-05-03

Last Posted Date: 2019-01-16

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 456

Registration Number: NCT02759198

Locations: 🇰🇷
KyungHee University Medical Center, Seoul, Korea, Republic of

Efficacy & Safety Study of YH22162 vs Telmisartan/Amlodipine in Patients With Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: telmisartan/amlodipine 40/5mg
Drug: YH22162 40/5/12.5 mg
Drug: YH22162 80/5/25 mg
Drug: telmisartan/amlodipine 80/5mg
Drug: telmisartan/amlodipine 40/5mg placebo
Drug: YH22162 40/5/12.5 mg placebo
Drug: telmisartan/amlodipine 80/5mg placebo
Drug: YH22162 80/5/25 mg placebo

First Posted Date: 2015-12-02

Last Posted Date: 2024-11-12

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 381

Registration Number: NCT02620163

Locations: 🇰🇷
Yuhan, Seoul, Korea, Republic of

PK Study of YH22189 FDC Compared to Combination of Telmisartan/Amlodipine and Rosuvastatin

Phase 1

Terminated

Conditions: Hypertension
Hyperlipidemia

Interventions: Drug: Crestor 20mg
Drug: Twynsta 80/10mg
Drug: YH22189

First Posted Date: 2015-11-18

Last Posted Date: 2017-02-01

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 123

Registration Number: NCT02608242

Locations: 🇰🇷
Chonbuk National University Hospital, Chunju, Korea, Republic of

Clinical Trial of YH14755 in Subjects With Dyslipidemia and Type II Diabetes

Phase 3

Completed

Conditions: Dyslipidemia
Type II Diabetes

Interventions: Drug: YH14755
Drug: Metformin
Drug: Rosuvastatin

First Posted Date: 2015-10-26

Last Posted Date: 2018-10-03

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 249

Registration Number: NCT02586129

Locations: 🇰🇷
Seoul National Universitiy Bundang Hospital, Seongnam-Si, Gyeonggi-Do, Korea, Republic of

A Phase II Clinical Trial of YH23537 in Patients With Chronic Periodontal Disease.

Phase 2

Completed

Conditions: Chronic Periodontitis

Interventions: Drug: YH23537 1000mg/day
Drug: YH23537 2000mg/day
Drug: YH23537 3000mg/day
Drug: placebo

First Posted Date: 2015-10-23

Last Posted Date: 2019-01-16

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 275

Registration Number: NCT02585596

Locations: 🇰🇷
Incheol Rhyu, Seoul, Korea, Republic of

A Trial to Evaluate the Efficacy and Safety of YH12852 in Patients With Functional Dyspepsia

Phase 2

Terminated

Conditions: Functional Dyspepsia

Interventions: Drug: YH12852 0.1 mg
Drug: YH12852 0.25 mg
Drug: YH12852 0.5 mg
Drug: Placebo

First Posted Date: 2015-10-05

Last Posted Date: 2022-01-13

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 12

Registration Number: NCT02567578

Locations: 🇰🇷
Samsung seoul hospital, Seoul, Korea, Republic of

Phase 1/2a Trial of YH12852 in Healthy Subjects and Patients With Functional Constipation

Phase 1

Completed

Conditions: Functional Constipation

Interventions: Drug: YH12852 IR 0.1mg
Drug: YH12852 DR1 2mg
Drug: YH12852 IR 0.05mg
Drug: YH12852 IR 0.5mg
Drug: YH12852 IR 2mg
Drug: YH12852 IR 0.3mg
Drug: YH12852 IR 1mg
Drug: Placebo
Drug: YH12852 IR 3mg
Drug: YH12852 DR1 0.5mg
Drug: YH12852 DR1 1mg
Drug: YH12852 DR1 4mg
Drug: Prucalopride 2mg
Drug: YH12852 DR2 8mg

First Posted Date: 2015-09-02

Last Posted Date: 2016-10-31

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 120

Registration Number: NCT02538367

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

PK Study of YH22162 FDC Compared to Combination of Twynsta and Hygroton

Phase 1

Completed

Conditions: Hypertension

Interventions: Drug: Telmisartan/Amlodipine 80/5 mg (FDC)
Drug: YH22162
Drug: Chlorthalidone 25mg

First Posted Date: 2015-07-14

Last Posted Date: 2015-09-25

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 180

Registration Number: NCT02496910

Locations: 🇰🇷
Chonbuk National University Hospital, Chunju, Korea, Republic of

Clinical Trial of YH14618 in Patients With Degenerative Disc Disease

Phase 2

Completed

Conditions: Disc Degenerative Disease

Interventions: Drug: Placebo
Drug: YH14618

First Posted Date: 2014-12-19

Last Posted Date: 2016-11-10

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 326

Registration Number: NCT02320019

Locations: 🇰🇷
Severance Hospital, Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy